Director at Microbot Medical (NASDAQ: MBOT) granted 10,000 stock options at $2.37

Rhea-AI Filing Summary

Microbot Medical Inc. director Laxminarain Prattipati received a grant of stock options covering 10,000 shares of common stock. The options have an exercise price of $2.37 per share, were granted on April 1, 2026, and expire on April 1, 2036.

Following this grant, Prattipati holds stock options for 10,000 shares directly. This is a compensation-related award, not an open‑market purchase or sale of Microbot Medical common stock.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Laxminarain Prattipati

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	10,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 10,000 shares (Direct)

Footnotes (1)

Key Figures

Options granted: 10,000 options Exercise price: $2.37 per share Expiration date: April 1, 2036 +1 more

4 metrics

Options granted 10,000 options Stock Option (Right to Buy) grant on April 1, 2026

Exercise price $2.37 per share Exercise price for 10,000 options on Microbot Medical common stock

Expiration date April 1, 2036 Option expiration for 10,000 granted options

Options held after transaction 10,000 options Total stock options directly held by the director following grant

Key Terms

Stock Option (Right to Buy), exercise price, expiration date

3 terms

Stock Option (Right to Buy) financial

"security_title: "Stock Option (Right to Buy)""

exercise price financial

"conversion_or_exercise_price: "2.3700" as the exercise price per share"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

expiration date financial

"expiration_date: "2036-04-01T00:00:00.000Z" as the expiration date"

The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Laxminarain Prattipati

(Last) (First) (Middle)

C/O MICROBOT MEDICAL INC.

175 DERBY ST., BLD. 27

(Street)

HINGHAM MASSACHUSETTS 02043

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Microbot Medical Inc. [ MBOT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$2.37	04/01/2026		A		10,000		04/01/2026	04/01/2036	Common Stock, par value $0.01 per share	10,000	$0	10,000	D

Explanation of Responses:

	/s/ Prattipati Laxminarain	04/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What insider transaction did MBOT director Laxminarain Prattipati report?

MBOT director Laxminarain Prattipati reported receiving a grant of stock options for 10,000 shares of Microbot Medical common stock. These options are a compensation award and do not represent an open‑market purchase or sale of existing shares.

How many Microbot Medical (MBOT) options were granted to the director?

The director was granted stock options covering 10,000 shares of Microbot Medical common stock. This entire 10,000‑share option position is shown as held directly after the transaction, reflecting a new derivative holding rather than a change in owned common shares.

What is the exercise price of the MBOT stock options granted to the director?

The granted options have an exercise price of $2.37 per share. This means the director can buy Microbot Medical common stock at $2.37 per share upon exercise, regardless of the market price at the time, until the options expire.

When do the newly granted Microbot Medical (MBOT) options expire?

The stock options granted to the director expire on April 1, 2036. Up to that expiration date, the director may choose to exercise the options at the fixed $2.37 per‑share exercise price, subject to any vesting or plan conditions not detailed here.

Did the MBOT director buy or sell common shares in this reported transaction?

No common shares were bought or sold; the director received a grant of stock options. This is a grant/award acquisition of derivative securities, providing the right to buy 10,000 shares in the future at $2.37 per share rather than an immediate market trade.

How many Microbot Medical (MBOT) stock options does the director hold after this grant?

After the reported grant, the director holds stock options for 10,000 shares of Microbot Medical common stock directly. This figure reflects the new compensation award and does not indicate any change in previously held common shares or other derivatives.